Radiopharm Theranostics Limited (RAD) AI Stock Analysis

• Market Cap: AU$58.35M
• Dividend Yield: N/A
• Average Volume (3M): 2.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: N/A
• EPS Growth: 53.41%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 2,333,980,200
• 10 Day Avg. Volume: 3,710,435
• 30 Day Avg. Volume: 2,477,173
• PEG Ratio: -0.02
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.05
• Price Target Upside: 150.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

Radiopharm Theranostics Limited is struggling with typical challenges faced by emerging biotech firms. The financial performance is constrained by significant losses and cash flow issues, despite a debt-free balance sheet. Technical analysis shows a bearish trend with potential for a short-term rebound. Valuation metrics highlight the speculative nature of the investment due to ongoing financial challenges and lack of profitability.

Positive Factors

Clinical Trials

The advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.

Strategic Focus

Radiopharm Theranostics focuses its therapeutic pipeline on biologically validated targets that have limited use in radiopharmaceuticals, reducing development risk and competition.

Negative Factors

Capital Raise

The AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Radiopharm Theranostics Limited Business Overview & Revenue Model

Company Description

Radiopharm Theranostics Limited (RAD) is a biotechnology company focused on the development and commercialization of radiopharmaceutical products for both diagnostic and therapeutic use in the field of oncology. The company leverages advanced medical imaging and targeted radiotherapy technologies to create innovative solutions that improve cancer diagnosis and treatment outcomes. By integrating theranostics, which combines therapeutic and diagnostic capabilities, Radiopharm aims to enhance the precision and effectiveness of cancer care.

How the Company Makes Money

Radiopharm Theranostics Limited generates revenue primarily through the development, licensing, and commercialization of its radiopharmaceutical products. The company's revenue streams include sales of diagnostic and therapeutic radiopharmaceuticals, milestone payments, and royalties from licensing agreements with pharmaceutical and biotechnology companies. Additionally, Radiopharm may enter into strategic partnerships to co-develop products, sharing both the costs and revenues. The company also invests in research and development to expand its product pipeline, aiming to introduce new and innovative solutions to the market, thereby increasing its revenue potential.

Radiopharm Theranostics Limited Financial Statement Overview

Summary

Radiopharm Theranostics Limited faces significant financial challenges typical of early-stage biotech firms. The income statement shows negative profit margins and increasing losses despite slight revenue growth. The balance sheet is moderately strong with no debt but is weakened by substantial net losses and high liabilities. Cash flow is negative, indicating significant cash outflows and a high burn rate, which necessitate continued external financing.

Income Statement

Radiopharm Theranostics Limited shows significant challenges in profitability. The gross profit margin and net profit margin are negative due to high costs and low revenue generation. There is a slight revenue growth from the previous year, but it is overshadowed by increasing losses. Overall, the income statement reflects ongoing financial struggles typical in the biotechnology industry, which often faces long R&D phases before profitability.

Balance Sheet

The company's balance sheet reveals a moderate equity position with no debt, which is a positive factor. However, the return on equity is negative due to substantial net losses. The equity ratio indicates a reliance on equity financing, common for early-stage biotech firms. The financial stability is challenged by declining equity and high liabilities, which are concerning for future financial health.

Cash Flow

Radiopharm Theranostics is experiencing negative operating and free cash flows, indicating cash outflow challenges. The company's ability to convert net income to cash flow is poor, as seen in the negative cash flow to net income ratios. Despite some financing inflows, the high cash burn rate is a significant risk, underscoring the need for continued external financing.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement		Total Revenue
1.38M	299.23K	292.36K	8.83K	0.00
	Gross Profit
-17.08M	-21.31M	-3.00M	-2.97M	0.00
	EBIT
-38.90M	-36.62M	-40.29M	-23.93M	-484.75K
	EBITDA
-36.53M	-45.38M	-31.19M	-18.04M	-484.75K
	Net Income Common Stockholders
-41.92M	-47.95M	-34.61M	-30.34M	-485.19K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
32.59M	18.58M	11.70M	26.98M	27.09K
	Total Assets
91.05M	72.04M	74.95M	83.38M	33.44K
	Total Debt
0.00	0.00	0.00	0.00	59.00K
	Net Debt
-32.59M	-18.58M	-11.70M	-26.98M	31.91K
	Total Liabilities
17.63M	44.68M	29.37M	20.42M	158.14K
	Stockholders Equity
73.42M	28.12M	44.38M	62.96M	-124.70K
Cash Flow		Free Cash Flow
-33.42M	-22.98M	-24.73M	-38.25M	-32.91K
	Operating Cash Flow
-33.42M	-22.98M	-23.20M	-9.91M	-32.91K
	Investing Cash Flow
3.00M	0.00	-1.53M	-28.37M	0.00
	Financing Cash Flow
64.51M	29.88M	9.22M	65.11M	60.00K

Radiopharm Theranostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 4.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RAD.

Radiopharm Theranostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAC	54 Neutral	AU$205.88M	―	-37.20%	―	―	32.02%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
PYC	53 Neutral	AU$699.91M	―	-112.97%	―	―	-84.82%
IMU	41 Neutral	$119.47M	―	-99.05%	―	―	-34.09%
BIT	36 Underperform	AU$3.32M	―	-119.28%	―	―	64.10%
RAD	34 Underperform	AU$58.35M	―	-108.26%	―	―	53.41%
OPT	30 Underperform	$738.77M	―		―	-24.46%	-7.90%

Radiopharm Theranostics Limited Corporate Events

Radiopharm Theranostics Advances in Clinical Trials and Secures Major Investment

Radiopharm Theranostics Limited announced significant advancements in its clinical trials and shareholder structure. Lantheus Holdings Inc. increased its stake to 12.16% through a US$5 million placement, providing funds to advance Radiopharm’s clinical pipeline. The company reported successful detection of brain metastases using RAD 101, a novel imaging agent, and positive preclinical data for RAD202, a HER2-targeting radiopharmaceutical. These developments underscore Radiopharm’s potential to improve cancer diagnostics and treatment, positioning it as a key player in the radiopharmaceutical industry.

Radiopharm Theranostics Initiates U.S. Phase 2b Imaging Study for Brain Metastasis

Radiopharm Theranostics has commenced dosing the first patient in a U.S. Phase 2b imaging study using 18F-RAD101 for suspected recurrent brain metastasis. This trial aims to evaluate the diagnostic performance of 18F-RAD101, a novel imaging small molecule targeting fatty acid synthase, in patients with confirmed recurrent brain metastases. The study’s primary objective is to assess the concordance between 18F-RAD101 positive lesions and conventional MRI imaging. The trial underscores Radiopharm’s commitment to advancing diagnostic precision in oncology, potentially improving treatment decisions for over 300,000 patients diagnosed with brain metastasis annually in the U.S.

Radiopharm Theranostics Reports Positive Data on RAD202 for HER2-Positive Tumors

Radiopharm Theranostics Limited has announced positive data from studies on its RAD202 product, presented at the European Molecular Imaging Meeting 2025. The data highlights the specific tumor targeting and favorable biodistribution of 68Ga-RAD202 for imaging, and the efficacy of 177Lu-RAD202 in reducing tumor volume and extending survival in HER2-positive solid tumors. These findings support ongoing clinical trials and suggest potential benefits for patients with advanced HER2-positive cancers, positioning the company as a leader in addressing unmet needs in oncology.

Radiopharm Theranostics Reports Reduced Losses for H2 2024

Radiopharm Theranostics Limited reported a 20.90% decrease in its loss from ordinary activities after tax for the half-year ended December 31, 2024, amounting to $18,725,453. Despite the reduction in losses, the company did not declare any dividends for the current or previous financial periods, and there were no changes in controlled entities. The financial statements were reviewed by an independent auditor, who issued an unmodified opinion, reflecting stability in the company’s financial reporting.

Radiopharm Theranostics to Present at TD Cowen Healthcare Conference

Radiopharm Theranostics Limited announced its participation in the TD Cowen Annual Healthcare Conference in Boston, where CEO Riccardo Canevari will present the company’s investment proposition. This presentation is a strategic move to attract investor interest, showcasing Radiopharm’s world-class pipeline and potential market leadership in radiopharmaceuticals, particularly in areas with high unmet medical needs.

Radiopharm Theranostics to Present at B. Riley Precision Oncology Conference

Radiopharm Theranostics Limited announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York on 28 February 2025. This event will feature over 35 biopharma and med-tech companies, providing Radiopharm an opportunity to present its innovative oncology solutions to a mix of institutional and professional investors, potentially enhancing its industry positioning and stakeholder engagement.

Radiopharm Theranostics Unveils Successful Detection of Brain Metastases with RAD 101

Radiopharm Theranostics Limited has announced successful clinical trial data showcasing the effectiveness of RAD 101 (18F-Pivalate) in detecting brain metastases using a novel PET-mpMRI imaging approach. This breakthrough demonstrates a high tumor-to-background ratio, promising a more sensitive detection method compared to the current standard of care, and could significantly improve diagnostic accuracy for suspected recurrent brain metastases. The ongoing Phase 2b trial in the United States aims to further evaluate the diagnostic performance of RAD 101, potentially enhancing the company’s positioning in the oncology radiopharmaceutical market.